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Introduction: Placental function is an important determinant of fetal growth, and fetal growth inﬂuences
obesity risk in childhood and adult life. Here we investigated how FTO and MC4R gene variants linked
with obesity relate to patterns of fetal growth and to placental FTO expression.
Methods: SouthamptonWomen's Survey children (n ¼ 1990) with measurements of fetal growth from 11
to 34 weeks gestation were genotyped for common gene variants in FTO (rs9939609, rs1421085) and
MC4R (rs17782313). Linear mixed-effect models were used to analyse relations of gene variants with
fetal growth.
Results: Fetuses with the rs9939609 A:A FTO genotype had faster biparietal diameter and head
circumference growth velocities between 11 and 34 weeks gestation (by 0.012 (95% CI 0.005 to 0.019)
and 0.008 (0.002e0.015) standard deviations per week, respectively) compared to fetuses with the T:T
FTO genotype; abdominal circumference growth velocity did not differ between genotypes. FTO geno-
type was not associated with placental FTO expression, but higher placental FTO expression was inde-
pendently associated with larger fetal size and higher placental ASCT2, EAAT2 and y þ LAT2 amino acid
transporter expression. Findings were similar for FTO rs1421085, and the MC4R gene variant was
associated with the fetal growth velocity of head circumference.
Discussion: FTO gene variants are known to associate with obesity but this is the ﬁrst time that the risk
alleles and placental FTO expression have been linked with fetal growth trajectories. The lack of an as-
sociation between FTO genotype and placental FTO expression adds to emerging evidence of complex
biology underlying the association between FTO genotype and obesity.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Obesity is a major public health problem as it increases the risk
of coronary heart disease, stroke, metabolic syndrome, some can-
cers and awide range of other diseases. Childrenwho are obese are
likely to continue to be obese when they become adults, high-
lighting the need for research into early determinants of obesity [1].iology Unit, University of
YD, UK.
).
r Ltd. This is an open access articleIn order to develop effective interventions it is important to un-
derstand the genetic and environmental determinants of obesity.
There is evidence suggesting critical windows during fetal and early
postnatal life, within which altered development may predispose
the individual to obesity in later life [2,3].
Genome wide association studies (GWAS) have been instru-
mental in the discovery of genes associated with obesity, including
the fat mass and obesity-associated (FTO) gene [4]. A common
variant in the FTO gene, rs9939609 has been identiﬁed that pre-
disposes to type 2 diabetes through an effect on body mass index
(BMI) [4e6]. FTO variants, including rs9939609 and rs1421085,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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[4,7e11] and throughout adult life [4e6,12], although associations
are less consistent in childhood. In addition, one study has shown
that FTO genotype is associated with fat mass in the ﬁrst 2 weeks of
life [13].
Associations have also been observed between the genotype of a
Single Nucleotide Polymorphism (SNP), rs17782313, near theMC4R
gene [14,15] and adult obesity. This SNP is also associated with
obesity in children [14,16,17] and one study reported an association
with changes in BMI over the ﬁrst two weeks of life [18]. MC4R
genotype is thought to act through an inﬂuence on satiety and it is
therefore interesting to investigate the effect of this SNP on the
fetus where conventional appetite mechanisms cannot play a part.
FTO is an RNA demethylase and could act through regulation of
mRNA stability [19]. However, no direct connection between
obesity associated variants and FTO expression and function has
been made. A recent study has demonstrated that obesity-
associated non-coding variants in FTO affect the expression of the
gene IRX3 in humans, mice and zebraﬁsh [20]. Obesity associated
SNPs in FTO were found to be associated with the expression of
IRX3, but not FTO, in the cerebellum of the human brain. IRX3 is a
homeobox gene involved in pattern formation in the early embryo
and is expressed at much lower levels in later life [21]. This raises
the possibility that the effects of FTO genotype on fetal growth and
postnatal obesity may have originated through IRX3 expression in
embryonic life.
Recent research has shown that FTO plays a key role in the
cellular sensing of amino acids and the regulation of cell growth
and global mRNA translation through the mTORC1 pathway [22].
This could explain why carriers of the obesity predisposing SNPs in
FTO not only consume more calories during test meals but also
show an alteration in nutrient preference [23] and a higher dietary
protein intake [24]. In utero, fetal growth is regulated by placental
amino acid transporters as they control the supply of nutrients to
the fetus. Thus FTO could potentially regulate fetal growth through
a mechanism of altered placental amino acid transport.
The primary aim of this study was to investigate the association
of obesity related SNPs (two FTO SNPs and one SNP near MC4R)
with fetal growth throughout gestation in children of the South-
ampton Women's Survey (SWS) [25]. The secondary aim of this
study was to investigate associations between FTO genotype, the
expression of this gene in the placenta, a fetal tissue, and placental
amino acid transporter expression.
2. Methods
Offspring of participants in the Southampton Women's Survey
were studied [25]. Between 1998 and 2007, 3158 babies were born
and data gathered on these babies both during the pregnancy via
ultrasound scans and after the birth.
Gestational age of the SWS babies was determined using an
algorithm based on last menstrual period, or where this was not
available early ultrasound data. Using Acuson 128 XP, Aspen and
Sequoia ultrasound machines calibrated to 1540 m/s; experienced
research ultrasonographers used standardised anatomical land-
marks to measure fetal head, abdominal circumference and bipar-
ietal diameter at 11, 19 and 34 weeks gestation.
The method of Royston [26] was used to calculate measures of
fetal size, correcting for exact gestational age at measurement.
Maternal smoking during pregnancy was assessed by ques-
tionnaire in early and late pregnancy.
DNA was extracted from the cord blood of SWS babies by the
salting out method and stored at 80 C. 1990 children from the
SWS cohort with DNA available were genotyped for the following
polymorphisms: rs9939609 and rs1421085 located in the FTO geneon chromosome 16, and rs17782313 located near theMC4R gene on
chromosome 18. Genotyping was performed by Kbiosciences
(Hoddesdon, Herts, UK) using a custom SNP panel and an in-house
calling algorithm. All three SNPs were found to be in HWE (chi
squared p value  0.05); call rate was  97%; 5% duplicates were
included with an error rate of 0%.
We analysed 99 SWS placentas based on availability of neonatal
data and Caucasian ethnicity and collection within 30 min of de-
livery. Five villous tissue samples were selected using a stratiﬁed
random sampling method and stored at 80 C and powdered in a
frozen tissue press. Total RNA was extracted from 30 mg tissue
using the Rneasy ﬁbrous tissue RNA isolation mini kit (Qiagen, UK)
according to the manufacturer's instructions. The integrity of total
RNA was conﬁrmed by agarose gel electrophoresis. Total RNA
(0.2 mg) was reverse transcribed with 0.5 mg random hexamer
primer, 200 units M-MLV reverse transcriptase, 25 units recombi-
nant RNasin ribonuclease inhibitor and 0.5 mM each of dATP, dCTP,
dGTP and dTTP in a ﬁnal reaction volume of 25 ml in 1 x MMLV
reaction buffer (Promega, Wisconsin, USA). All 99 samples were
produced in one batch to reduce variation.
Oligonucleotide probes and primers for FTO and the amino acid
transporter genes were designed using the Roche (West Sussex,
UK) ProbeFinder version 2.45 for human. Probes were supplied by
Roche from the human universal probe library and primers were
synthesised by Eurogentec (Seraing, Belgium). FTO
(NM_001080432.2): Forward 50- cacaacctcggtttagttcca -30, Reverse
50- aaatataatccaaggttcctgttgag -30, probe #53. ASCT2
(NM_005628.2): Forward 50-gaggaatatcaccggaacca-30, Reverse 50-
aggatgttcatcccctcca-30, probe 43. EAAT2 (NM_004171.3): Forward
50-aaaatgctcattctccctctaatc-30, Reverse 50-gccactagccttagcatcca-30,
probe 78. yþLAT2 (NM_001076785.1): Forward 50-gctgtgatccccca-
tacct-30, Reverse 50-ggcacagttcacaaatgtcag-30, probe 66. Control
genes were selected using the geNormTM human Housekeeping
Gene Selection Kit (Primer Design Limited, Southampton, UK).
FTO and amino acid transporter mRNA expression levels were
quantiﬁed by real-time reverse transcriptase PCR using a Roche
LightCycler 480. For Roche universal probe library probes the cycle
parameters were 95 C for 5 min, followed by 45 cycles of 95 C for
10 s, 60 C for 30 s and 72 C for 1 s. For primer design Perfect
Probes (control genes) the cycle parameters were 95 C for 10 min,
followed by 40e50 cycles of 95 C for 15 s, 50 C for 30 s and 72 C
for 15 s. Intra-assay CV's for each gene were 5e8%. Each of the 99
samples was run on the same plate in triplicate. All mRNA levels are
presented relative to the geometric mean of the three control
genes, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta polypeptide (YWHAZ), ubiquitin C (UBC)
and topoisomerase (TOP1) [27].
2.1. Statistical analysis
Statistical procedures were performed in Stata version 12 (Sta-
taCorp, Texas, USA) and SPSS version 21 (IBM, Armonk, New York).
Babies with congenital growth abnormalities and babies of mothers
listed as having non-white ethnicity were excluded from analysis.
Anthropometric variables were checked for normality and then
standardised to z-scores. For cross-sectional analysis genotypes
were coded according to the additive model (0, 1 or 2 copies of the
risk allele). The risk allele was considered to be A for FTO
rs9939609, C for FTO rs1421085 and C for MC4R rs17782313. Uni-
variate linear regressions were run with each genotype separately
as predictor variable for each outcome (CRL, BPD, HC and AC),
adjusting for sex, maternal smoking during pregnancy, pregnancy
weight gain category (IOM (2009)) and pre-pregnancy maternal
BMI. Results were expressed in SDs of change in outcome per unit
increase in number of risk alleles.
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gitudinal analyses. Intercept and gestational age were entered into
the model as random effects and a genotype x gestational age
interaction was also included to assess growth velocity in the
measurements over time. Sex, maternal smoking, pregnancy
weight gain category and pre-pregnancy maternal BMI were
included as covariates. Genotype was included as a categorical
covariate because exploratory analysis (see Fig. 1) indicated that
this was more appropriate.
Partial correlations of FTO gene expression in the placenta and
anthropometric variables, were calculated, controlling for sex.
Neonatal variables were additionally adjusted for gestational age
and mode of delivery (Caesarean or vaginal).
Bonferroni correction was applied to account for multiple
testing for each of the main hypotheses tested.
3. Results
Analysis of fetal growth, was based on 1990 SWS singleton
births with available fetal measurements and FTO or MC4R geno-
type or placental gene RNA data. Supplementary Figure 1 shows the
numbers of SWS babies with available DNA and genotype. Table 1
shows summary statistics for the SWS cohort divided into groups
according towhether genotypewas available or not. There does not
appear to be much difference between these groups.
The minor allele frequency for the FTO rs9939609 genotype in
the SWS was A ¼ 0.41, similar to the minor allele frequency quoted
in HapMap [29] for Caucasians (CEU: A ¼ 0.45).
3.1. Cross-sectional analysis
Table 2 shows there were a number of potentially signiﬁcantFig. 1. The means and 95% CIs of Royston biparietal diameter z-score at all three available ges
biparietal diameter z-score decreases with increasing gestational age, however for the A:A g
biparietal diameter for the A:A genotype has a signiﬁcantly different fetal growth trajectory,
by linear mixed-effect modelling (p ¼ 0.0009).associations at the 5% level between FTO and MC4R SNPs and fetal
anthropometric measurements. While none of these associations
remained signiﬁcant at p < 0.05 after a strict Bonferroni correction,
many of the fetal measures are correlated, so a Bonferroni correc-
tion is likely to be overly conservative. A retrospective power
calculation indicated that to ﬁnd a difference in means of fetal
measure z-scores between genotype groups of 0.18, 1446 SWS
children would be required to achieve a power of 90% at a 5% sig-
niﬁcance level.
Fig. 1 shows the means and 95% conﬁdence intervals for bipar-
ietal diameter z-score at 11, 19 and 34 weeks for the FTO rs9939609
genotypes. At 11 weeks gestation, fetuses with the A:A genotype
tended to have a lower biparietal diameter z-score than either the
T:A genotype or the T:T genotype. At 19 weeks, biparietal diameter
z-score was similar in the three genotypes. However, at 34 weeks
gestation, fetuses with the A:A genotype had a higher biparietal
diameter z-score than either of the other two genotypes. This im-
plies a different fetal biparietal diameter growth trajectory in fe-
tuses with the A:A genotype compared to the other two genotypes,
with a smaller 11 week size followed by a faster growth velocity for
the A:A genotype.3.2. Linear mixed-effect models
Maternal weight gain category and sex were signiﬁcantly asso-
ciated with biparietal diameter, head circumference and abdominal
circumference when included in linear mixed-effect models
(p < 0.0001), with males having a larger measurement than fe-
males. Maternal smoking in pregnancy was associated with bipar-
ietal diameter and head circumference (p  0.05), with the fetuses
of mothers who did not smoke in pregnancy having a larger head
size. Maternal smoking in pregnancy was not associated withtational ages for each rs9939609 genotype separately. For the T:T and T:A genotypes the
enotype biparietal diameter z-score increases with gestational age. This shows that the
with fetal biparietal diameter growing faster than the T:T genotype. This was conﬁrmed
Table 1
Summary statistics for the Southampton Women’s Survey Cohort, showing subgroups deﬁned by availability of genotype
Variable Genotype available Genotype not available
N Mean Std. Dev. N Mean Std. Dev.
11 week scan: Crown rump length (mm) 1593 53.48 9.07 808 53.32 8.88
11 week scan: Biparietal diameter (mm) 1247 18.72 2.59 609 18.66 2.52
19 week scan: Biparietal diameter (mm) 1912 45.5 2.54 961 45.75 2.49
34 week scan: Biparietal diameter (mm) 1869 86.98 3.6 896 87.09 3.51
11 week scan: Head circumference (mm) 1223 70.46 9.41 602 69.99 8.94
19 week scan: Head circumference (mm) 1912 168.43 8.53 960 168.79 8.53
34 week scan: Head circumference (mm) 1869 317.94 10.98 902 317.42 11.02
Birth: Head circumference (mm) 1955 350.33 13.47 848 348.74 14.87
11 week scan: Abdominal circumference (mm) 1152 55.99 7.91 555 55.96 7.42
19 week scan: Abdominal circumference (mm) 1902 146.46 8.95 960 146.97 8.75
34 week scan: Abdominal circumference (mm) 1958 307.87 15.42 940 307.22 15.02
Birth: Abdominal circumference (mm) 1953 318 20.18 846 315.22 21.86
Birth: Birthweight (g) 1976 3485.49 506.91 984 3373.68 623.77
Maternal pre-pregnancy BMI (kg/m2) 1964 25.35 4.77 999 25 4.78
Sex 1982 51.6% male 1008 52.5% male
IOM maternal weight gain 1744 28.5% adequate 600 31.7% adequate
maternal smoking 1944 16.9% yes 887 16.1% yes
maternal pre-eclampsia 1982 2.8% yes 1008 3.3% yes
maternal gestational diabetes 1982 1.1% yes 1008 1.0% yes
SGA (WHO UK z-score ) 1976 7.5% yes 984 8.8% yes
Table 2
Regression results for cross-sectional analysis of fetal measurements, controlling for sex, maternal smoking during pregnancy, gestational weight gain and maternal BMI. Beta
values represent change in fetal measure per risk allele, p values are uncorrected.
Variable FTO rs9939609 FTO rs1421085 MC4R rs17782313
beta se p value beta se p value beta se p value
11 week scan: Royston CRL z-score -0.066 0.04 0.099 -0.081 0.039 0.04 0.088 0.046 0.056
11 week scan: Royston BPD z-score -0.074 0.043 0.083 -0.076 0.042 0.073 -0.026 0.049 0.592
19 week scan: Royston BPD z-score -0.023 0.032 0.472 -0.033 0.032 0.299 0.025 0.038 0.509
34 week scan: Royston BPD z-score 0.034 0.035 0.33 0.022 0.034 0.526 0.05 0.04 0.211
11 week scan: Royston HC z-score -0.11 0.042 0.013 -0.1 0.042 0.016 -0.061 0.049 0.22
19 week scan: Royston HC z-score -0.031 0.032 0.332 -0.035 0.031 0.266 0.03 0.037 0.41
34 week scan: Royston HC z-score -0.011 0.034 0.74 -0.016 0.034 0.644 0.059 0.04 0.136
11 week scan: Royston AC z-score -0.071 0.047 0.128 -0.083 0.047 0.076 -0.048 0.053 0.373
19 week scan: Royston AC z-score -0.027 0.032 0.396 -0.03 0.031 0.332 0.047 0.036 0.201
34 week scan: Royston AC z-score -0.022 0.033 0.51 -0.025 0.033 0.446 0.054 0.039 0.16
Birth weight z-score (also controlling for GA) 0.004 0.03 0.888 0.012 0.03 0.678 0.052 0.035 0.142
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was signiﬁcantly associated with head circumference and abdom-
inal circumference (p  0.007) but not with biparietal diameter.
Linear mixed-effect models for two measures of head size,
namely biparietal diameter and head circumference z-score,
measured at 11, 19 and 34 weeks gestation, showed that FTO ge-
notype rs9939609was strongly associatedwith the growth velocity
of head size, as there was a signiﬁcant interaction between geno-
type and gestational age (p ¼ 0.0009 for biparietal diameter and
p ¼ 0.014 for head circumference). This demonstrates that FTO
genotypes have different growth trajectories. When abdominal
circumference z-score was used as the dependent variable, there
was no association between the growth velocity of abdominal
circumference and FTO genotype. The results from linear mixed-
effect models analysing the rs1421085 genotype were very
similar to those using the rs9939609 genotype due to the high LD
between them (data not shown). When the MC4R genotype
rs17782313 was used as a predictor in the longitudinal models
there were no signiﬁcant associations between this SNP and the
growth velocity of biparietal diameter and abdominal circumfer-
ence, but there was an association between MC4R and head
circumference growth velocity (p ¼ 0.013) across the three gesta-
tional ages of 11, 19 and 34 weeks.
Interactions between FTO genotype and sex, and between FTOgenotype and maternal smoking were investigated but no signiﬁ-
cant interactions were found (p > 0.05).3.3. Placental FTO relative RNA level
Placental FTO relative RNA level was available for 99 offspring
(mean 1.23, sd 0.27).
No associationwas observed between FTO genotype and relative
RNA levels of FTO in the placenta (assessed by ANOVA, p
value ¼ 0.914, Fig. 2).
Table 3 shows partial correlations, controlling for sex, of fetal
anthropometric measurements with placental FTO relative gene
expression. Neonatal measures were adjusted for sex, gestational
age and mode of delivery. Several fetal anthropometric measure-
ments appeared highly correlated with the FTO expression in the
placenta (Table 3, Fig. 3). Head circumference at 34 weeks was
signiﬁcantly associated with placental FTO relative gene expression
after Bonferroni correction and neonatal head circumference
showed a borderline association.
We also attempted to measure the levels of IRX3 in the term
human placenta, but found that levels were too low to measure
reliably.
Associations were also found between FTO mRNA expression
and the expression of placental amino acid transporters. FTO
Fig. 3. The correlation between FTO relative RNA level in the placenta and 34 week
Royston head circumference z-score (r ¼ 0.324, p ¼ 0.001, n ¼ 98). Males were plotted
using circles and females using squares.
Fig. 2. There is no association between FTO genotype and expression of FTO in the
placenta (ANOVA p value ¼ 0.914).
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EAAT2 (rho ¼ 0.22, p ¼ 0.027) and yþLAT2 (rho ¼ 0.37, p ¼ 0.0002)
mRNA expression.4. Discussion
We have shown novel associations between FTO genotypes
rs9939609 and rs1421085 and two measures of fetal head growth.
From 11 to 34 weeks gestation fetuses with the homozygous FTO
risk genotype (A:A or C:C) showed a higher velocity of biparietal
diameter and head circumference growth in comparison with the
other genotypes (T:A or T:C and T:T). Results were also in accor-
dance with previous publications showing that maternal smoking
is signiﬁcantly associated with smaller fetal head size [30]. Trends
were also identiﬁed in our cross-sectional analyses between the
FTO SNPs and a SNP nearMC4R and head circumference and crown-
rump length, although these did not survive Bonferroni correction.
For the above associations, the effect was in accordance with
published literature for adults and babies [14,15,18] as the addition
of each risk allele increased the measurements. We did not observe
associations between theMC4R SNP and fetal growth trajectories of
biparietal diameter and abdominal circumference, or between FTO
SNPs and the fetal abdominal circumference growth trajectory.
Few authors have investigated the possible effect of FTO SNPs on
fetal growth. Marsh et al. [31] reported that there was no evidenceTable 3
Partial correlations, controlling for sex, of anthropometric measurements and placental
Variable Co
11 week scan: Royston CRL z-score 0.2
11 week scan: Royston BPD z-score 0.3
19 week scan: Royston BPD z-score 0.2
34 week scan: Royston BPD z-score 0.2
11 week scan: Royston HC z-score 0.2
19 week scan: Royston HC z-score 0.1
34 week scan: Royston HC z-score 0.3
11 week scan: Royston AC z-score 0.3
19 week scan: Royston AC z-score 0.1
34 week scan: Royston AC z-score 0.2
Birth weight (controlling for sex, GA and mode of delivery) 0.2
Neonatal HC (controlling for sex, GA and mode of delivery) 0.2
Neonatal AC (controlling for sex, GA and mode of delivery) 0.1of any difference in fetal growth between the sexes and between
rs9930609 genotype up to 28 weeks gestation. After 28 weeks
gestation they observed a signiﬁcant association between the
rs9939609 A:A genotype and fetal growth restriction in non-
smoking Australian mothers and fetal growth enhancement for
mothers who smoked. This differs from our results as we did not
observe a signiﬁcant interaction between maternal smoking and
genotype. However, the two sets of results are difﬁcult to compare
as our measurements were made by research staff following strict
measurement protocols and we have considered the growth tra-
jectory over all available gestational ages in the Southampton
Women's Survey cohort; in contrast Marsh et al. used routinely
collected data and analysed each trimester of pregnancy separately.
Placental function is an important determinant of fetal growth
and may predispose to obesity later in life [32]. Our observations
that FTO gene expression was correlated with birth weight are
consistent with those of previous studies [33e35]. In addition we
found novel associations between FTO gene expression and fetal
growth parameters. However, placental FTO expression was not
associated with either of the FTO genotypes in our SWS cohort,FTO relative RNA level
rrelation Signiﬁcance (2-tailed) N
89 0.020 66
59 0.014 47
12 0.045 91
41 0.018 97
05 0.172 47
80 0.090 91
24 0.001 98
45 0.023 44
79 0.091 91
42 0.017 98
04 0.046 99
76 0.006 99
65 0.107 99
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tations in Intron 1 of the FTO gene control the expression of IRX3
[20]. Our observation that FTO expression was independent of its
genotype is consistent with the suggestion that the associations
between FTO genotype and fetal growth are not mediated via FTO
expression. If FTO is not regulated by genotype the question arises
as to what is regulating FTO expression. FTO may be involved in
nutrient sensing and regulate the mTOR pathway and, in the
placenta, FTO gene expression may be related to maternal nutri-
tional status. We observed that FTO gene expression was related to
the expression of speciﬁc amino acid transporters in the placenta.
As amino acid transfer is essential for fetal development this pro-
vides a potential mechanism by which FTO expression within the
placenta may affect placental function and therefore fetal growth
[36].
Consistent with the observation that FTO genotype is associated
with fetal head growth; in humans a ‘loss of function’ mutation in
the FTO gene has been found to induce postnatal growth retarda-
tion and malformations in the head and brain [37] Other recent
studies have reported that carriers of common FTO gene poly-
morphisms show both a reduction in frontal lobe volume of the
brain [38] and an impaired verbal ﬂuency performance [39], It was
interesting that FTO genotype (thought to be controlling IRX3 gene
expression) and FTO gene expression (which is independent of FTO
genotype rs9939609) were both associated with fetal head growth
in our study, however it is not clear whether there is a biological
relationship underlying this. FTO knockout mice have altered head
growth [40], but as knocking out the FTO gene also knocks out the
FTO SNPs regulating IRX3 it is not clear whether the effects of FTO
knockout is due to the loss of FTO gene expression or the loss of
regulation of the IRX3 gene.
Fetal growth is a complex trait which is likely to be determined
by multiple genetic [41] and environmental [42] factors. The cu-
mulative effect of multiple variants could produce clinically rele-
vant differences in growth. The detection of novel genetic variants
associated with fetal growth has the potential to identify molecular
mechanisms connected with growth and can yield insights of bio-
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